NCT04060173View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 5, 2019

Primary Completion Date

December 29, 2019

Study Completion Date

February 7, 2020

Conditions
HyperuricemiaGout
Interventions
DRUG

ABP-671

ABP-671 is an investigational drug

OTHER

Placebo

Matching placebo

Trial Locations (1)

85283

Celerion, Tempe

Sponsors
All Listed Sponsors
lead

Atom Therapeutics Co., Ltd

INDUSTRY

NCT04060173 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 | Biotech Hunter | Biotech Hunter